At the Forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA www.TapImmune.com
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.
Corporate Presentation TAPIMMUNE July 2012
A New Frontier in Immunotherapy
TapImmune is an Immunotherapy company specializing in the development of the most comprehensive and innovative immunotherapeutics in cancer and infectious diseases.
OPPORTUNITY Corporate Presentation July 2012
Why invest in TapImmune now?
Unique and Broad product opportunities in cancer & infectious disease Two Phase I Clinical Trials ready to progress to Phase II HER2/neu breast cancer vaccine potential blockbuster Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential HUGE market opportunities in multiple therapeutic indications PolyStart™ expression vector is a significant advance in vaccine technologies Strong management & advisory team
Leverage of key collaborations with leading institutions Series of preclinical and clinical value inflexion points Significantly undervalued and poised for significant growth
An approach with the potential to change lives and excellent entry level valuation
TAPIMMUNE
Corporate Presentation July 2012
Harnessing the Power of Immune System
Leading Immunotherapy Approach: CANCER • • •
Making tumors visible to T-cells Stimulating T-killer cells AND T-helper cells Applicable to broad patient populations
INFECTIOUS DISEASE • • •
Up-regulation of Antigen Presentation Stimulating T-killer cells & T-helper cells Applicable Multiple Infectious Diseases and Biothreats
The Immune System Corporate Presentation July 2012
The body’s immune system is designed to fight cancer & viral infections Cancers evade the immune system allowing tumor growth Reasons:
The Cancer Markers (antigens) are NOT presented to the Immune System
Low or Absent T A P (Antigen Transporter) Epitopes are NOT Naturally Processed (NPE)
T cell response is SHORT lived (No Helper Cells CD4)
T cell response is NOT a KILLER cell response (CD8)
PROBLEM: cancer evades the immune system and current approaches do not address ALL the reasons adequately
The Immunotherapy Space Corporate Presentation July 2012
New Frontier in Treatment of Cancer
Traditional Approaches Chemotherapy, Radiation, Surgery, Small Molecules
New Immunotherapies Immune Checkpoint Blockade (BMS; Merck) Monoclonal antibodies (Roche) T-Cell Therapies Ex-Vivo: Adoptive T-cell transfer (LBIO;Juno) Dendritic cell transfer (NWBIO;DNDN; PBMD) In Vivo: Antigen stimulation (ONTY;GALE;IMUC) BOTH Antigen presentation & T Cell stimulation (TPIV) PROBLEM: To Stimulate the Immunse System to Effectively KILL Tumors
The TapImmune Approach Corporate Presentation July 2012
Prime BOTH sides of the tumor Killing equation Proprietary peptide antigens used to stimulate a broad based • T - Helper cell response (CD4) LONG-LIVED • KILLER T-cells to actually KILL the tumor (CD8)
These Proprietary Antigens allow us to treat: • Wider patient populations • Multiple Indications • Multiple Therapeutic Areas (Cancer and Infectious Disease) SOLUTION: most COMPREHENSIVE immunotherapeutic in development
Product Pipeline
Corporate Presentation July 2012
Product
Indication
TPIV100 Class II antigens
Her2/neu breast cancer
TPIV110 Class I + II antigens Her2/neu breast cancer
TPIV200 Folate Receptor Alpha Ovarian/breast cancer Q2 2014
TPIV120 (PolyStart™ Class I/II antigens) TPIV 300 (Class I antigens)
Her2/neu breast cancer
Smallpox Emerging viral threats
Preclinical
Phase I
Phase II
Lead Clinical Programs Corporate Presentation July 2012
Trial 1: Her2neu Breast Cancer - Mayo Clinic Rochester MN
HER2/neu positive breast cancer is one of most aggressive forms
HER2/neu is overexpressed in ~ 30% breast cancer patients (total 220,000 /yr) Roche’s monoclonal antibody, Herceptin (current standard of care) can only treat ~ 20% of these patients (+$6 billion sales in 2013) Herceptin does not stimulate Killer T-cells – it slows/retards tumor growth In Contrast: We believe TapImmune’s comprehensive combination of Killers and Helpers has the potential to provide Long Lasting Immune Response in upto 84% of the HER2/neu positive patient population. A $ Multi-Billion product potential meeting an UNSATISFIED CLINICAL NEED in a very LARGE Market Herceptin Facts: Late Stage Survival improved by 4.5 Months. Early stage treatment resulted in a 9.5% improvement on recurrence. 70% of Her2neu+ patients do NOT respond to treatment
HER2/neu Clinical Status Corporate Presentation July 2012
Her2neu Breast Cancer - Mayo Clinic Rochester MN
Phase l
Class II antigens (4 epitopes NPE) discovered in breast cancer patients - Clin. Cancer Res. (2010) 16, 825-83 • 22 Patients post Herceptin • 6 x monthly intradermal + GMCSF Interim safety checkpoint completed Positive Immune responses on first 6 patients (interim data) Excellent Results – Support progression to Phase ll
Phase lb/ll
Class II + Class I (p373-382) antigens (4+1) To start Q4, 2014 Small safety study 100-150 patient multicenter phase II
HER2/neu Clinical Program Corporate Presentation July 2012
Her2neu Breast Cancer - Mayo Clinic Rochester MN
Leading HER2/neu Vaccine Candidate Peptide Antigens to stimulate BOTH: •
T-helper cells – Long Lasting • Antigens discovered in breast cancer patients • Naturally Processed Epitopes (NPE’s)
•
Killer T-cells (p373-382) - Kills Tumor Cells
Compared to NeuVax by Galena: 4-5x greater KILLING activity against human tumor cell targets See: J.Immonol. (2013) 190, 479-488
SOLUTION: most COMPREHENSIVE immunotherapeutic in development
Lead Clinical Programs Corporate Presentation July 2012
Trial 2: Stage II/II Ovarian & Breast Cancer - Mayo Clinic
Folate Receptor Alpha is expressed over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy Very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. US alone, approximately 30,000 ovarian cancer patients newly diagnosed every year. Phase llb/2 advancement expected in late 2014. Orphan Drug Application – Pending FDA Another $ Multi-Billion product potential with an UNSATISFIED CLINICAL NEED
URGEN CLINCAL NEED - LARGE MARKET OPPORTUNITY
Ovarian Trial Clinical Status Corporate Presentation July 2012
T
Trial 2: Ovarian & Breast Cancer (Folate Alpha) - Mayo Clinic Rochester MN
Phase l
22 patients with Stage II-III Breast, Ovarian, Peritoneal, Fallopian Tube Cancer
Interim safety checkpoint completed Positive Immune responses observed Promising Interim Results – Support progression to Phase ll
Phase ll Expected to Start in 2014 with Orphan Drug Application - FDA Pending
Antigens Applicable to Ovarian and Triple Negative Breast Cancer
TapImmune: 2014 Upcoming Milestones Q1
Corporate
Trial 1: Breast Cancer
Trial 2: Ovarian Cancer
Q2
Restructure
Q3
Q4
NASDAQ Start Phase Ib/II
HER2/neu+ breast cancer Folate Alpha Licensing of Breast/Ovarian Phase I program
Pre-Clinical
PolyStart™
Bio-Threat
Viral Disease
Start Phase II
PolyStart IP
Finish Preclinical FDA meeting
Smallpox Partnership
Multiple Inflection Points and Value Drivers
Corporate Presentation COLLABORATORS & ADVISORS July 2012
World Class Team
Dr Keith Knutson (Vaccine & Gene Therapy Institute of Florida/Mayo Clinic): Director, Cancer Immunology and Immunotherapy Program, VGTI; Adjunct Faculty - Immunology, Mayo Clinic Dr Greg Poland: (Mayo Clinic) Head of Vaccines; Infectious disease/biodefense
Dr Mac Cheever (Fred Hutchinson Cancer Research Center) Director Solid Tumor Research; Professor of Medicine/Oncology at the University of Washington (Seattle) & Director of the NCI-funded Cancer Immunotherapy Trials Network (CITN) Mark Reddish Advisor: Development , Board Product Development: Cancer vaccines and Biodefense: Biomira, ID Biomedical, Baxter, Bayer AG
Denis Corin Corporate Finance
Management and Advisors Corporate Presentation July 2012
Glynn Wilson, PhD
Bob Florkiewicz, PhD
CEO 25 years experience in product & corporate development
Head of Research 25 years experience, academic and biotech
SmithKline Beecham, Ciba-Geigy, Tacora
Denis Corin Corporate Finance Beckman, Novartis
Synergen, TSRI, UW, GSK, Seed IP Law Group
Mark Reddish Advisor: Development, Board 25 years experience in cancer vaccines and biodefense Biomira, ID Biomedical, Baxter, Bayer AG
Corporate Presentation CAP STRUCTURE and COMPS July 2012
Reorganized Feb 2014
TPIV - TAPIMMUNE INC Capital Structure Shares Outstanding Public Float Debt Elimination Market cap Stock Price
Post Restructure 16,000,000 2,000,000 ~$5,000,000 ~$30,000,000 $2.00
Comparrisons in Immunotherapy and Biotech
GALE (Galena) LBIO (Lion Bio) INO (Inovio) DNDN (Dendreon) NWBO (Nothwest Bio)
Shares Out
Market Cap
105,240,000 26,000,000 240,150,000 157,490,000 53,400,000
$ $ $ $ $
250,000,000 180,000,000 565,550,000 453,560,000 317,730,000
Stock Price $2.50 $6.50 $2.39 $2.88 $5.99
OPPORTUNITY Corporate Presentation July 2012
Why invest in TapImmune now?
Unique and Broad product opportunities in cancer & infectious disease Two Phase I Clinical Trials ready to progress to Phase II HER2/neu breast cancer vaccine potential blockbuster Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential HUGE market opportunities in multiple therapeutic indications PolyStart™ expression vector is a significant advance in vaccine technologies Strong management & advisory team
Leverage of key collaborations with leading institutions Series of preclinical and clinical value inflexion points Significantly undervalued and poised for significant growth
An approach with the potential to change lives and excellent entry level valuation
CONTACT Glynn Wilson Chief Executive Officer
[email protected] Denis Corin Corporate Finance
[email protected]